ZAI LAB LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ZAI LAB LIMITED (ZLAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 7.50 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-26
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 7.50M shares, a 61.27% decline from fiscal 2024.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 19.37M shares, a 363.02% increase from fiscal 2023.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 4.18M shares, a 42.33% decline from fiscal 2022.
- ZAI LAB LIMITED share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 7.25M shares, a 4643.86% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|
| 2025-12-31 | 7.50M shares 10-K · filed 2026-02-26 | |
| 2024-12-31 | 19.37M shares 10-K · filed 2025-02-27 | |
| 2023-12-31 | 4.18M shares 10-K · filed 2024-02-27 | |
| 2022-12-31 | 7.25M shares 10-K · filed 2023-03-01 | |
| 2021-12-31 | 152.91K shares 10-K · filed 2022-03-01 | |
| 2020-12-31 | 687.88K shares 10-K · filed 2021-03-01 | |
| 2020-06-30 | 46.41K shares 6-K · filed 2020-09-11 | |
| 2019-12-31 | 35.20K shares 10-K · filed 2021-03-01 | |
| 2019-06-30 | 18.14K shares 6-K · filed 2020-09-11 | |
| 2018-12-31 | 290.33K shares 10-K · filed 2021-03-01 | |
| 2017-12-31 | 843.41K shares 20-F · filed 2020-04-29 | |
| 2016-12-31 | 84.00 shares 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |